COL4A3在过敏性哮喘中降解且降解产物可预测抗IgE治疗反应
本研究在ALLIANCE队列(儿童病例/对照n=134/35,成人病例/对照n=149/31)中检测血清COL4A3降解标志物C4Ma3及细胞因子,并在小鼠过敏性气道炎症模型中验证其机制。结果发现C4Ma3在成人和儿童哮喘中均升高,与更严重、伴急性加重的过敏性哮喘表型相关,且依赖肥大细胞糜蛋白酶。C4Ma3在囊性纤维化合并ABPA患者中显著升高,基线水平可预测抗IgE治疗成功(诊断OR 31.5)。
要点
- 血清C4Ma3在成人和儿童哮喘中均升高,与更严重、伴加重的过敏性哮喘表型相关。
- 小鼠模型中C4Ma3依赖肥大细胞糜蛋白酶。
- 基线C4Ma3可预测过敏性未控制哮喘患者抗IgE治疗反应(诊断OR 31.5)。
核心结论
- C4Ma3水平依赖肺肥大细胞糜蛋白酶,在严重、伴加重的过敏性哮喘表型中升高。
- C4Ma3可能作为预测抗IgE治疗反应的新型生物标志物。
研究设计与样本
- 在ALLIANCE队列中检测血清C4Ma3和细胞因子,儿童病例/对照n=134/35,成人病例/对照n=149/31。
- 小鼠过敏性气道炎症模型通过卵清蛋白致敏、雾化激发及poly(cytidylic-inosinic)滴入诱导。
- 使用糜蛋白酶抑制剂Fulacimstat确定肥大细胞糜蛋白酶在COL4A3降解中的作用。
- 检测囊性纤维化患者(n=14)、囊性纤维化合并ABPA患者(n=9)及严重过敏性未控制哮喘患者(n=19)的COL4A3降解。
- 采用哮喘控制测试评估奥马珠单抗(抗IgE)治疗。
主要发现
- 成人和儿童哮喘患者血清C4Ma3水平均升高,且与更严重、伴加重的过敏性哮喘表型相关。
- 实验性哮喘小鼠模型中C4Ma3依赖于肥大细胞糜蛋白酶。
- 囊性纤维化合并ABPA患者血清C4Ma3显著升高。
- 基线血清C4Ma3可预测过敏性未控制哮喘患者抗IgE治疗成功(诊断OR 31.5)。
关键数值与推荐
- 基线C4Ma3预测抗IgE治疗成功的诊断OR为31.5。
临床怎么用
- 对过敏性未控制哮喘患者,可考虑检测基线血清C4Ma3以预测奥马珠单抗治疗反应。
- C4Ma3升高提示更严重、伴加重的过敏性哮喘表型,需加强评估与管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Asthma is a heterogeneous syndrome substantiating the urgent requirement for endotype-specific biomarkers. Dysbalance of fibrosis and fibrolysis in asthmatic lung tissue leads to reduced levels of the inflammation-protective collagen 4 (COL4A3). OBJECTIVE: To delineate the degradation of COL4A3 in allergic airway inflammation and evaluate the resultant product as a biomarker for anti-IgE therapy response. METHODS: The serological COL4A3 degradation marker C4Ma3 (Nordic Bioscience, Denmark) and serum cytokines were measured in the ALLIANCE cohort (paediatric cases/controls: n=134/n=35; adult cases/controls: n=149/n=31). Exacerbation of allergic airway disease in mice was induced by sensitising to ovalbumin (OVA), challenge with OVA aerosol and instillation of poly(cytidylic-inosinic). Fulacimstat (chymase inhibitor; Bayer) was used to determine the role of mast cell chymase in COL4A3 degradation. Patients with cystic fibrosis (n=14) and cystic fibrosis with allergic bronchopulmonary aspergillosis (ABPA; n=9) as well as patients with severe allergic uncontrolled asthma (n=19) were tested for COL4A3 degradation. Omalizumab (anti-IgE) treatment was assessed using the Asthma Control Test. RESULTS: Serum levels of C4Ma3 were increased in asthma in adults and children alike and linked to a more severe, exacerbating allergic asthma phenotype. In an experimental asthma mouse model, C4Ma3 was dependent on mast cell chymase. Serum C4Ma3 was significantly elevated in cystic fibrosis plus ABPA and at baseline predicted the success of the anti-IgE therapy in allergic, uncontrolled asthmatics (diagnostic OR 31.5). CONCLUSION: C4Ma3 levels depend on lung mast cell chymase and are increased in a severe, exacerbating allergic asthma phenotype. C4Ma3 may serve as a novel biomarker to predict anti-IgE therapy response.
引用
- Weckmann M, Bahmer T, Sand JM, et al. COL4A3 is degraded in allergic asthma and degradation predicts response to anti-IgE therapy. Eur Respir J. 2021. PMID: 34326188. doi:10.1183/13993003.03969-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。